Alliance Global Partners Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $2.2
Alliance Global Partners Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $2.2
Alliance Global Partners維持買入NeuroOne Medical Tech，將目標
Alliance Global Partners analyst Ben Haynor maintains NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy and lowers the price target from $3.25 to $2.2.
Alliance Global Partners分析師Ben Haynor維持NeuroOne Medical Tech(納斯達克股票代碼：NMTC)的買入，並將目標價從3.25美元下調至2.2美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。